Human Clostridium difficile infection: Inhibition of NHE3 and microbiota profile

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 308, Issue 6, 2014, Pages G497-G509

  Engevik, Melinda A ^a   Engevik, Kristen A ^a   Yacyshyn, Mary Beth ^a   Wang, Jiang ^a   Hassett, Daniel J ^a   Darien, Benjamin ^b   Yacyshyn, Bruce R ^a,c   Worrell, Roger T ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

C. difficile; Diarrhea; Gut microbiota; Intestinal organoids; NHE3

Indexed keywords

CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN B; MESSENGER RNA; PROTEIN; SODIUM; SODIUM PROTON EXCHANGE PROTEIN 3; VANCOMYCIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER 3; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ADULT; AGED; ALKALINITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTEROIDETES; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DOWN REGULATION; FECES ANALYSIS; FEMALE; FIRMICUTES; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; INTESTINE FLORA; MALE; MICROINJECTION; MIDDLE AGED; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOBACTERIA; SUPERNATANT; CASE CONTROL STUDY; CELL CULTURE; COLON; CYTOPLASM; FECES; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MICROFLORA; PH; PLURIPOTENT STEM CELL; PSEUDOMEMBRANOUS COLITIS;

ADULT; AGED; BACTERIAL PROTEINS; BACTERIAL TOXINS; CASE-CONTROL STUDIES; CELLS, CULTURED; CLOSTRIDIUM DIFFICILE; COLON; DOWN-REGULATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; MALE; MICROBIOTA; MIDDLE AGED; ORGANOIDS; PLURIPOTENT STEM CELLS; RNA, MESSENGER; SODIUM; SODIUM-HYDROGEN ANTIPORTER;

EID: 84929593876     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00090.2014     Document Type: Article

References (77)

1. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 77: 2367-2375, 2009
2. Badger VO, Ledeboer NA, Graham MB, Edmiston CE Jr. Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J Parenter Enteral Nutr 36: 645–662, 2012
3. Barbieri JT, Riese MJ, Aktories K. Bacterial toxins that modify the actin cytoskeleton. Annu Rev Cell Dev Biol 18: 315–344, 2002
4. Barman M, Unold D, Shifley K, Amir E, Hung K, Bos N, Salzman N. Enteric salmonellosis disrupts the microbial ecology of the murine gastrointestinal tract. Infect Immun 76: 907–915, 2008
5. Bauer MP, van Dissel JT. Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents 33, Suppl 1: S51–56, 2009
6. Bezerra CN, Girardi AC, Carraro-Lacroix LR, Reboucas NA. Mechanisms underlying the long-term regulation of NHE3 by parathyroid hormone. Am J Physiol Renal Physiol 294: F1232–F1237, 2008
7. Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 21: 224–226, 1995
8. Borriello SP. Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 41, Suppl C: 13–19, 1998
9. Caldwell DR, Arcand C. Inorganic and metal-organic growth requirements of the genus Bacteroides. J Bacteriol 120: 322–333, 1974
10. Caldwell DR, Keeney M, Barton JS, Kelley JF. Sodium and other inorganic growth requirements of bacteroides amylophilus. J Bacteriol 114: 782–789, 1973
11. Campbell RJ, Giljahn L, Machesky K, Cibulskas-White K, Lane LM, Porter K, Paulson JO, Smith FW, McDonald LC. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol 30: 526–533, 2009
12. Castillo M, Martin-Orue SM, Manzanilla EG, Badiola I, Martin M, Gasa J. Quantification of total bacteria, enterobacteria and lactobacilli populations in pig digesta by real-time PCR. Vet Microbiol 114: 165–170, 2006
13. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197: 435-438, 2008
14. Croswell A, Amir E, Teggatz P, Barman M, Salzman NH. Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection. Infect Immun 77: 2741–2753, 2009
15. Deneve C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 33, Suppl 1: S24–28, 2009
16. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6: e280, 2008
17. Dingle T, Mulvey GL, Humphries RM, Armstrong GD. A real-time quantitative PCR assay for evaluating Clostridium difficile adherence to differentiated intestinal Caco-2 cells. J Med Microbiol 59: 920–924, 2010
18. Dubberke ER, Butler AM, Reske KA, Agniel D, Olsen MA, D’Angelo G, McDonald LC, Fraser VJ. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 14: 1031–1038, 2008
19. Dubberke ER, Haslam DB, Lanzas C, Bobo LD, Burnham CA, Grohn YT, Tarr PI. The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge. Zoonoses Public Health 58: 4–20, 2011
20. Engevik MA, Aihara E, Montrose MH, Shull GE, Hassett DJ, Worrell RT. Loss of NHE3 alters gut microbiota composition and influences Bacteroides thetaiotaomicron growth. Am J Physiol Gastrointest Liver Physiol 305: G697–G711, 2013
21. Fang A, Gerson DF, Demain AL. Production of Clostridium difficile toxin in a medium totally free of both animal and dairy proteins or digests. Proc Natl Acad Sci USA 106: 13225–13229, 2009
22. Fierer N, Jackson JA, Vilgalys R, Jackson RB. Assessment of soil microbial community structure by use of taxon-specific quantitative PCR assays. Appl Environ Microbiol 71: 4117–4120, 2005
23. Fite A, Macfarlane GT, Cummings JH, Hopkins MJ, Kong SC, Furrie E, Macfarlane S. Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction. Gut 53: 523-529, 2004
24. Gawenis LR, Stien X, Shull GE, Schultheis PJ, Woo AL, Walker NM, Clarke LL. Intestinal NaCl transport in NHE2 and NHE3 knockout mice. Am J Physiol Gastrointest Liver Physiol 282: G776–G784, 2002
25. Guo X, Xia X, Tang R, Zhou J, Zhao H, Wang K. Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 47: 367–373, 2008
26. Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, Hibi T, Roers A, Yagita H, Ohteki T, Yoshimura A, Kanai T. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 13: 711–722, 2013
27. Hayashi H, Sakamoto M, Kitahara M, Benno Y. Diversity of the Clostridium coccoides group in human fecal microbiota as determined by 16S rRNA gene library. FEMS Microbiol Lett 257: 202–207, 2006
28. Hayashi H, Szaszi K, Coady-Osberg N, Furuya W, Bretscher AP, Orlowski J, Grinstein S. Inhibition and redistribution of NHE3, the apical Na+/H+ exchanger, by Clostridium difficile toxin B. J Gen Physiol 123: 491–504, 2004
29. Hazenberg MP, Van de Boom M, Bakker M, Van de Merwe JP. Effect of antibiotics on the human intestinal flora in mice. Antonie Van Leeuwenhoek 49: 97–109, 1983
30. Jafari NV, Kuehne SA, Bryant CE, Elawad M, Wren BW, Minton NP, Allan E, Bajaj-Elliott M. Clostridium difficile modulates host innate immunity via toxin-independent and dependent mechanism(s). PLoS One 8: e69846, 2013
31. Jank T, Aktories K. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 16: 222–229, 2008
32. Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17: 15R–22R, 2007
33. Janoir C, Deneve C, Bouttier S, Barbut F, Hoys S, Caleechum L, Chapeton-Montes D, Pereira FC, Henriques AO, Collignon A, Monot M, Dupuy B. Adaptive strategies and pathogenesis of Clostridium difficile from in vivo transcriptomics. Infect Immun 81: 3757–3769, 2013
34. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156: 3216–3223, 2010
35. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 330: 257–262, 1994
36. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467: 711–713, 2010
37. Lay C, Rigottier-Gois L, Holmstrom K, Rajilic M, Vaughan EE, de Vos WM, Collins MD, Thiel R, Namsolleck P, Blaut M, Dore J. Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol 71: 4153–4155, 2005
38. Lee J, Kim S, Jung J, Oh BS, Kim IS, Hong SK. Analysis of total bacteria, enteric members of -proteobacteria and microbial communities in seawater as indirect indicators for quantifying biofouling. Environ Eng Res 14: 19–25, 2009
39. Ley RE, Lozupone CA, Hamady M, Knight R, Gordon JI. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol 6: 776–788, 2008
40. Lyras D, O’Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. Toxin B is essential for virulence of Clostridium difficile. Nature 458: 1176–1179, 2009
41. Malakooti J, Sandoval R, Amin MR, Clark J, Dudeja PK, Ramaswamy K. Transcriptional stimulation of the human NHE3 promoter activity by PMA: PKC independence and involvement of the transcription factor EGR-1. Biochem J 396: 327–336, 2006
42. Manichanh C, Reeder J, Gibert P, Varela E, Llopis M, Antolin M, Guigo R, Knight R, Guarner F. Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Res 20: 1411-1419, 2010
43. Mitchell MJ, Laughon BE, Lin S. Biochemical studies on the effect of Clostridium difficile toxin B on actin in vivo and in vitro. Infect Immun 55: 1610–1615, 1987
44. Naaber P, Mikelsaar RH, Salminen S, Mikelsaar M. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 47: 591–598, 1998
45. Naaber P, Smidt I, Stsepetova J, Brilene T, Annuk H, Mikelsaar M. Inhibition of Clostridium difficile strains by intestinal Lactobacillus species. J Med Microbiol 53: 551–554, 2004
46. Navaneethan U, Giannella RA. Thinking beyond the colon-small bowel involvement in clostridium difficile infection. Gut Pathog 1: 7, 2009
47. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 72: 6040–6049, 2004
48. O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 28: 1219–1227, 2007
49. Orrhage K, Nord CE. Bifidobacteria and lactobacilli in human health. Drugs Exp Clin Res 26: 95–111, 2000
50. Ott SJ, Musfeldt M, Ullmann U, Hampe J, Schreiber S. Quantification of intestinal bacterial populations by real-time PCR with a universal primer set and minor groove binder probes: a global approach to the enteric flora. J Clin Microbiol 42: 2566–2572, 2004
51. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial- associated risk factors for Clostridium difficile infection. Clin Infect Dis 46, Suppl 1: S19–31, 2008
52. Quinkler M, Bujalska IJ, Kaur K, Onyimba CU, Buhner S, Allolio B, Hughes SV, Hewison M, Stewart PM. Androgen receptor-mediated regulation of the alpha-subunit of the epithelial sodium channel in human kidney. Hypertension 46: 787–798, 2005
53. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficilerelated mortality rates, United States, 1999–2004. Emerg Infect Dis 13: 1417–1419, 2007
54. Rolfe RD, Helebian S, Finegold SM. Bacterial interference between Clostridium difficile and normal fecal flora. J Infect Dis 143: 470–475, 1981
55. Salzman NH, de Jong H, Paterson Y, Harmsen HJ, Welling GW, Bos NA. Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria. Microbiology 148: 3651-3660, 2002
56. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, Teggatz P, Barman M, Hayward M, Eastwood D, Stoel M, Zhou Y, Sodergren E, Weinstock GM, Bevins CL, Williams CB, Bos NA. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 11: 76–83, 2010
57. Sato R, Tanaka M. Intestinal distribution and intraluminal localization of orally administered Clostridium butyricum in rats. Microbiol Immunol 41: 665–671, 1997
58. Savidge TC, Pan WH, Newman P, O’Brien M, Anton PM, Pothoulakis C. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125: 413–420, 2003
59. Schultheis PJ, Clarke LL, Meneton P, Miller ML, Soleimani M, Gawenis LR, Riddle TM, Duffy JJ, Doetschman T, Wang T, Giebisch G, Aronson PS, Lorenz JN, Shull GE. Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat Genet 19: 282–285, 1998
60. Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, Kurata S. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int 45: 86–90, 2003
61. Sekirov I, Tam NM, Jogova M, Robertson ML, Li Y, Lupp C, Finlay BB. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect Immun 76: 4726–4736, 2008
62. Sghir A, Gramet G, Suau A, Rochet V, Pochart P, Dore J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol 66: 2263–2266, 2000
63. Singh V, Raheja G, Borthakur A, Kumar A, Gill RK, Alakkam A, Malakooti J, Dudeja PK. Lactobacillus acidophilus upregulates intestinal NHE3 expression and function. Am J Physiol Gastrointest Liver Physiol 303: G1393–G1401, 2012
64. Sjogren YM, Jenmalm MC, Bottcher MF, Bjorksten B, Sverremark- Ekstrom E. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy 39: 518–526, 2009
65. Smith JA, Cooke DL, Hyde S, Borriello SP, Long RG. Clostridium difficile toxin A binding to human intestinal epithelial cells. J Med Microbiol 46: 953–958, 1997
66. Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol 16: 107–114, 2008
67. Syrbu SI, Cohen MB. An enhanced antigen-retrieval protocol for immunohistochemical staining of formalin-fixed, paraffin-embedded tissues. Methods Mol Biol 717: 101–110, 2011
68. Tasteyre A, Barc MC, Collignon A, Boureau H, Karjalainen T. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun 69: 7937–7940, 2001
69. Taylor RH, Borriello SP, Taylor AJ. Isolation of Clostridium difficile from the small bowel. Br Med J 283: 412, 1981
70. Testore GP, Nardi F, Babudieri S, Giuliano M, Di Rosa R, Panichi G. Isolation of Clostridium difficile from human jejunum: identification of a reservoir for disease? J Clin Pathol 39: 861–862, 1986
71. Tsutaoka B, Hansen J, Johnson D, Holodniy M. Antibiotic-associated pseudomembranous enteritis due to Clostridium difficile. Clin Infect Dis 18: 982–984, 1994
72. Valiquette L, Pepin J, Do XV, Nault V, Beaulieu AA, Bedard J, Schmutz G. Prediction of complicated Clostridium difficile infection by pleural effusion and increased wall thickness on computed tomography. Clin Infect Dis 49: 554–560, 2009
73. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18: 247–263, 2005
74. Waligora AJ, Barc MC, Bourlioux P, Collignon A, Karjalainen T. Clostridium difficile cell attachment is modified by environmental factors. Appl Environ Microbiol 65: 4234–4238, 1999
75. Wee B, Poels JA, McCafferty IJ, Taniere P, Olliff J. A description of CT features of Clostridium difficile infection of the small bowel in four patients and a review of literature. Br J Radiol 82: 890-895, 2009
76. Wells JM, Brugman S. Building additional complexity to in vitro-derived intestinal tissues. Stem Cell Res Ther 4: S1, 2013
77. Wilson KH, Sheagren JN, Freter R, Weatherbee L, Lyerly D. Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J Infect Dis 153: 547–551, 1986.